GlycoNex Incorporation (4168.TWO)
- Previous Close
18.75 - Open
18.85 - Bid 18.40 x --
- Ask 18.50 x --
- Day's Range
18.30 - 18.90 - 52 Week Range
15.60 - 31.85 - Volume
124,146 - Avg. Volume
145,322 - Market Cap (intraday)
1.996B - Beta (5Y Monthly) 0.42
- PE Ratio (TTM)
-- - EPS (TTM)
-1.86 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date Aug 5, 2013
- 1y Target Est
--
GlycoNex Incorporation engages in the development of cancer drugs using glycosphingolipid antigen and human monoclonal antibody technologies in Taiwan. The company's development pipeline for the treatment of solid tumors includes GNX102, a humanized monoclonal antibody, currently under phase 1 clinical stage; GNX201, an antibody drug currently under lead optimization stage; GNX202, an antibody drug currently under preclinical stage; and GNX203 and GNX204, antibody drugs currently under target validation stage. It is also involved in the development of SPD (Denosumab), a humanized IgG2 antibody that is in preclinical stage for the treatment of osteoporosis and oncology; and SEA (Aflibercept), a vascular endothelial growth factor binding fusion protein, currently under lead optimization stage for the treatment of ophthalmology and oncology. The company was incorporated in 2001 and is based in New Taipei City, Taiwan.
www.glyconex.com.twRecent News: 4168.TWO
View MorePerformance Overview: 4168.TWO
Trailing total returns as of 5/22/2025, which may include dividends or other distributions. Benchmark is TSEC CAPITALIZATION WEIGHTED ST (^TWII) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 4168.TWO
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 4168.TWO
View MoreValuation Measures
Market Cap
2.03B
Enterprise Value
1.63B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
106.60
Price/Book (mrq)
2.02
Enterprise Value/Revenue
85.87
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-9.78%
Return on Equity (ttm)
-18.28%
Revenue (ttm)
19.03M
Net Income Avi to Common (ttm)
-201.48M
Diluted EPS (ttm)
-1.86
Balance Sheet and Cash Flow
Total Cash (mrq)
395.15M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-192.7M